Coherus Oncology, Inc. (CHRS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-26

Key Insights

Coherus Oncology's Chief Financial Officer, Bryan J. McMichael, has acquired 112,500 restricted stock units (RSUs) and 225,000 stock options, indicating potential confidence in the company's future performance.
The RSUs vest 50% in May 2027 and 50% in March 2029, while the stock options vest over 4 years, suggesting a long-term commitment from the executive.
The substantial equity grants, both in RSUs and stock options, may align the CFO's interests with those of shareholders and signal the company's focus on long-term growth.

Want the newest filings?

This analysis covers the filing from 2026-01-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-26

The reporting person, Dennis M. Lanfear, was granted 375,000 restricted stock units (RSUs) on January 23, 2026, which will vest over time as he continues his service as the President and CEO of Coherus Oncology, Inc.
Lanfear also holds 432,684 shares of Coherus Oncology's common stock through a trust and 86,965 shares through an LLC, indicating his significant equity ownership in the company.
Lanfear was granted a stock option to purchase 750,000 shares of Coherus Oncology's common stock, which will vest over time as he continues his service with the company.

Filed: 2026-01-22

The filing indicates that Dennis M. Lanfear, the President and CEO of Coherus Oncology, Inc., has disposed of 11,839 shares of the company's common stock. This appears to be a routine transaction to cover tax liabilities associated with the vesting of restricted stock units.
Lanfear also holds a significant indirect beneficial ownership in the company, with 432,684 shares held through the Lanfear Revocable Trust and 86,965 shares held through Lanfear Capital Advisors, LLC. This suggests a substantial alignment of his interests with those of the company's shareholders.
The filing does not indicate any significant changes in Lanfear's overall ownership position, suggesting a relatively stable leadership and ownership structure at Coherus Oncology.

Filed: 2026-01-22

The reporting person, Bryan J. McMichael, the Chief Financial Officer of Coherus Oncology, Inc., has disposed of 1,715 shares of common stock through an automatic withholding transaction to pay related tax liability, indicating he continues to hold a significant position in the company.
The transaction occurred on January 20, 2026, suggesting ongoing insider activity and engagement with the company's equity compensation program.
The reported transaction price of $1.55 per share may provide insight into the current market valuation of Coherus Oncology's stock.

Other reports for Coherus Oncology, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.